Alkeon Capital Management
AXSM icon

Alkeon Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Alkeon Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-100,000
Closed -$2.02M – 136
2019
Q3 		$2.02M Hold
100,000
– – 0.01% 133
2019
Q2 		$2.58M Buy
100,000
+20,000
+25% +$401K 0.01% 139
2019
Q1 		$1.14M Buy
+80,000
New +$743K 0.01% 127

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Alkeon Capital Management's AXSM Position: Q4 2019 in Review

Alkeon Capital Management sold out of Axsome Therapeutics (AXSM) in Q4 2019, closing a stake of 100,000 shares — an estimated $2.02M sold.

Alkeon Capital Management first reported a position in AXSM in Q1 2019 and held it in 3 quarters. The position peaked at $2.58M in Q2 2019. 169 funds tracked by Wall St. Rank hold AXSM as of Q4 2019.

  • Alkeon Capital Management reported no remaining Axsome Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Alkeon Capital Management sold 100,000 Axsome Therapeutics shares in Q4 2019, an estimated $2.02M.
  • Alkeon Capital Management first reported a position in Axsome Therapeutics in Q1 2019 and held it in 3 quarters.
  • Alkeon Capital Management's Axsome Therapeutics position peaked at $2.58M in Q2 2019.
  • 169 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2019.

Based on Alkeon Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.